Ubs Group Ag Hepion Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.31 - $1.06 $4,361 - $14,914	14,070 New	14,070 $10,000
Q3 2022 Nov 10, 2022	BUY	$0.51 - $10.4 $5,508 - $112,320	10,800 New	10,800 $5,000
Q2 2022 Aug 10, 2022	SELL	$0.57 - $1.22 $1,051 - $2,250	-1,845 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.93 - $1.29 $7,685 - $10,660	-8,264 Reduced 81.75%	1,845 $2,000
Q4 2021 Feb 14, 2022	SELL	$1.14 - $1.58 $43,595 - $60,422	-38,242 Reduced 79.09%	10,109 $12,000
Q3 2021 Nov 15, 2021	BUY	$1.39 - $2.1 $35,230 - $53,226	25,346 Added 110.18%	48,351 $74,000
Q2 2021 Aug 13, 2021	SELL	$1.56 - $2.26 $70,507 - $102,145	-45,197 Reduced 66.27%	23,005 $46,000
Q1 2021 May 12, 2021	BUY	$1.77 - $2.98 $119,609 - $201,376	67,576 Added 10794.89%	68,202 $125,000
Q4 2020 Feb 11, 2021	SELL	$1.58 - $3.64 $1,524 - $3,512	-965 Reduced 60.65%	626 $1,000
Q3 2020 Nov 12, 2020	BUY	$2.84 - $4.59 $4,518 - $7,302	1,591 New	1,591 $5,000
Q1 2020 May 01, 2020	SELL	$1.15 - $5.74 $3,820 - $19,068	-3,322 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.25 - $6.99 $931 - $2,893	-414 Reduced 11.08%	3,322 $18,000
Q3 2019 Nov 14, 2019	BUY	$2.09 - $4.12 $7,808 - $15,392	3,736 New	3,736 $9,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $45.7M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.